Key facts
- It has raised $193.6M; the latest was Later Stage VC ($98.0M) in Jan 2026.
- Notable investors include Invest-NL (Investment Company), EQT Life Sciences, ROM Utrecht Region, EQT, Partners in Equity — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Kaleido
- ·The full record, as it builds
Funding rounds
No funding rounds for Kaleido are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kaleido
Developer of medical devices designed to be used for the treatment of diabetes. The company's device comes with multiple insulin pumps and a rechargeable and wireless handset wherein the pump system is integrated with the Diabeloop system to offer automated insulin delivery, enabling users to control their glucose level by choosing a conventional or patch pump style as per their blood group and live on their terms.
- Sector
- Healthcare
- HQ
- Utrecht, Netherlands
- Founded
- 2013
- Employees
- 181
- Website
- hellokaleido.com/
- Ownership
- Privately Held (backing)
Kaleido doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kaleido shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kaleido in its N-PORT filings yet. We sweep new filings monthly.